Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort

Abstract

Mineral and bone disorder (MBD) in chronic kidney disease (CKD) is tightly linked to cardiovascular disease (CVD). In this study, we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular (CV) outcomes and mortality. In 5 217 participants of the German CKD (GCKD) study enrolled with an estimated glomerular filtration rate (eGFR) between 30–60 mL·min⁻¹ per 1.73 m² or overt proteinuria, serum osteoprotegerin (OPG), C-terminal fibroblast growth factor-23 (FGF23), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX1), procollagen 1 intact N-terminal propeptide (P1NP), phosphate, calcium, and 25-OH vitamin D were measured at baseline. Participants with missing values among these parameters (n = 971) were excluded, leaving a total of 4 246 participants for analysis. During a median follow-up of 6.5 years, 387 non-CV deaths, 173 CV deaths, 645 nonfatal major adverse CV events (MACEs) and 368 hospitalizations for congestive heart failure (CHF) were observed. OPG and FGF23 were associated with all outcomes, with the highest hazard ratios (HRs) for OPG. In the final Cox regression model, adjusted for CV risk factors, including kidney function and all other investigated biomarkers, each standard deviation increase in OPG was associated with non-CV death (HR 1.76, 95% CI: 1.35–2.30), CV death (HR 2.18, 95% CI: 1.50–3.16), MACE (HR 1.38, 95% CI: 1.12–1.71) and hospitalization for CHF (HR 2.05, 95% CI: 1.56–2.69). Out of the nine biomarkers examined, stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.

References

[1] Jankowski J et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation, 2021, 143: 1157-1172

[2] Matsushita K et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat. Rev. Nephrol., 2022, 18: 696-707

[3] Vervloet MG et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol., 2014, 2: 427-436

[4] Lunyera J, Scialla JJ. Update on chronic kidney disease mineral and bone disorder in cardiovascular disease. Semin. Nephrol., 2018, 38: 542-558

[5] Reiss AB et al. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Atherosclerosis, 2018, 278: 49-59

[6] Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319

[7] Tschiderer L et al. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: literature-based meta-analysis involving 26 442 participants. PLoS One, 2017, 12: e0183910

[8] Oh TR et al. Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study). Kidney Res. Clin. Pr., 2022, 41: 200-208

[9] Marthi A et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J. Am. Soc. Nephrol., 2018, 29: 2015-2027

[10] Nizet A et al. Bone alkaline phosphatase: an important biomarker in chronic kidney disease—mineral and bone disorder. Clin. Chim. Acta, 2020, 501: 198-206

[11] Drechsler C et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin. J. Am. Soc. Nephrol., 2011, 6: 1752-1759

[12] Brown JP et al. Current use of bone turnover markers in the management of osteoporosis. Clin. Biochem., 2022, 109-110: 1-10

[13] Floege J et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol. Dial. Transpl., 2011, 26: 1948-1955

[14] Pilz S et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis., 2011, 58: 374-382

[15] Scialla JJ et al. Biomarkers of vascular calcification and mortality in patients with ESRD. Clin. J. Am. Soc. Nephrol., 2014, 9: 745-755

[16] Kaminska J et al. Circulating osteoprotegerin in chronic kidney disease and all-cause mortality. Int. J. Gen. Med., 2021, 14: 2413-2420

[17] Marques GL et al. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5. Sci. Rep., 2021, 11

[18] Semb AG et al. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb. Vasc. Biol., 2009, 29: 975-980

[19] Omland T et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 2008, 51: 627-633

[20] Bucay N et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev., 1998, 12: 1260-1268

[21] Bjerre M. Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus, 2013, 2

[22] Smith ER, Holt SG, Hewitson TD. FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-beta autoinduction. Int. J. Biochem. Cell Biol., 2017, 92: 63-78

[23] Isakova T et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J. Am. Soc. Nephrol., 2018, 29: 579-590

[24] Yang H et al. Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis. Biomark. Med., 2016, 10: 547-556

[25] Wang L et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc Qual. Outcomes, 2012, 5: 819-829

[26] Borrelli S et al. Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS One, 2018, 13: e0202417

[27] Lopes MB et al. Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS. Nephrol. Dial. Transpl., 2020, 35: 1794-1801

[28] Eddington H et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2010, 5: 2251-2257

[29] Da J et al. Serum phosphorus and progression of CKD and mortality: a meta-analysis of cohort studies. Am. J. Kidney Dis., 2015, 66: 258-265

[30] Mehrotra R et al. No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int., 2013, 84: 989-997

[31] Menon V et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am. J. Kidney Dis., 2005, 46: 455-463

[32] Fahrleitner-Pammer A et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Min. Res., 2008, 23: 1850-1858

[33] Filipowicz R et al. Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Clin. J. Am. Soc. Nephrol., 2013, 8: 26-32

[34] Bager CL et al. Bone and soft tissue turnover in relation to all-cause mortality in postmenopausal women. J. Gerontol. A Biol. Sci. Med. Sci., 2019, 74: 1098-1104

[35] Sambrook PN et al. High bone turnover is an independent predictor of mortality in the frail elderly. J. Bone Miner. Res., 2006, 21: 549-555

[36] Zelniker TA et al. Biomarker of collagen turnover (C-terminal telopeptide) and prognosis in patients with non- ST -elevation acute coronary syndromes. J. Am. Heart Assoc., 2019, 8: e011444

[37] An Z et al. Biomarkers in patients with myocardial fibrosis. Open Life Sci., 2017, 12: 337-344

[38] Hayer MK et al. Defining myocardial abnormalities across the stages of chronic kidney disease: a cardiac magnetic resonance imaging study. JACC Cardiovasc. Imaging, 2020, 13: 2357-2367

[39] Park M et al. Urinary markers of fibrosis and risk of cardiovascular events and death in kidney transplant recipients: the FAVORIT trial. Am. J. Transpl., 2017, 17: 2640-2649

[40] Bouma-de Krijger A, Vervloet MG. Fibroblast growth factor 23: are we ready to use it in clinical practice? J. Nephrol., 2020, 33: 509-527

[41] Bożentowicz-Wikarek M et al. C-terminal to intact fibroblast growth factor 23 ratio in relation to estimated glomerular filtration rate in elderly population. Kidney Blood Press. Res., 2016, 41: 519-526

[42] Sharma S et al. Intact and C-terminal FGF23 assays-do kidney function, inflammation, and low iron influence relationships with outcomes? J. Clin. Endocrinol. Metab., 2020, 105: e4875-e4885

[43] Emrich IE et al. Strength of fibroblast growth factor 23 as a cardiovascular risk predictor in chronic kidney disease weaken by ProBNP adjustment. Am. J. Nephrol., 2019, 49: 203-211

[44] Liu C et al. Systematic review and meta-analysis of plasma and urine biomarkers for CKD outcomes. J. Am. Soc. Nephrol., 2022, 33: 1657-1672

[45] Eckardt KU et al. The German chronic kidney disease (GCKD) study: design and methods. Nephrol. Dial. Transpl., 2012, 27: 1454-1460

[46] Titze S et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German chronic kidney disease (GCKD) cohort. Nephrol. Dial. Transpl., 2015, 30: 441-451

Funding

Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)(2022_EKES.03)

German Society of Internal Medicine 361357

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)(01ZX1912B)

KfH (Kuratorium für Heimdialyse und Nierentransplantation e.V.—Stiftung Präventivmedizin- no grant number

Deutsche Forschungsgemeinschaft (German Research Foundation)(322900939)